亚洲A∨无码一区二区三区_久久亚洲综合色一区二区三区_一区二区三区免费电影_亚洲AV日韩AV天堂一区二区三区

修改這篇文章 : Development of CMO/CDMO

推廣信息

分類目錄: *

信息類型: *

公司庫品牌庫產(chǎn)品庫供應(yīng)信息求購信息服務(wù)項目解決方案業(yè)界資訊新聞事件展會信息名詞解釋知識庫文章招聘信息網(wǎng)址連接圖片庫資料下載創(chuàng)業(yè)加盟招商合作促銷活動其它信息

標(biāo)題: *

詳細(xì)內(nèi)容: *

Before 1996, there were few CDMO/CMO companies. APIs and intermediates were mainly produced by pharmaceutical factories or supplied by chemical enterprises, mainly distributed in Europe. From 1996 to 2007, the CDMO industry emerged: Patheon entered the field of drug CDMO and distributed the markets in Europe and North America; Catalent entered into the production of oral preparations and became independent from its parent company; Lonza, the leader of CDMO, formally intervened in the field of biopharmaceuticals and began to expand its distribution. From 2007 to 2016, the number of innovative drugs approved increased, heavy drugs came out frequently. Pharmaceutical enterprises adjusted their production capacity one after another. The increase of outsourcing proportion helped the industry to develop rapidly again. Since 2013, the CDMO industry has grown at a rate of 10-15%, especially the small molecular API business. Upstream and Downstream of CMO/CDMO Industry Chain The upstream is the chemical industry. For biopharmaceuticals, mainly Bio-culture raw materials industry, CMO enterprises usually cooperate with multiple suppliers to optimize the industrial chain, control the cost of raw materials, and select suppliers to control the quality of raw materials. In order to ensure the timely supply of products and the quality of products, pharmaceutical manufacturers will inspect and audit the technical capability, quality management system and EHS system of CMO enterprises, and establish long-term strategic cooperative relations with a few core suppliers. Driving Force of CMO/CDMO Development: Continuous Growth of New Drug Research and Development According to statistics, since 2001, the global innovation drug R&D pipeline has maintained a sustained growth, and has accelerated in recent years. At the same time, the global innovation drug R&D expenditure has also maintained a growth rate of 2-3% in recent years. Pharmaceutical enterprises can not fully cover all R&D projects, so it is necessary to outsource some projects or businesses.

上傳圖片:

* (jpg , gif , png) format

聯(lián)系人信息

姓名: *

電子信箱: *

手機:

公司名稱:

聯(lián)系電話:

詳細(xì)地址:

郵政編碼:

網(wǎng)址URL:

其他

關(guān)鍵詞:

有效期:

* 天

管理密碼:*

* 刪除/修改

更換密碼:

* 如有必要，可重新設(shè)置新的管理密碼

刪除此信息

*